interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Ethinyl Estradiol; Norelgestromin

Generic competition · all medicines · read 12 November 2026

Is there a generic of Ethinyl Estradiol; Norelgestromin, and who makes it?

Ethinyl Estradiol; Norelgestromin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 12.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Ethinyl Estradiol; Norelgestromin2 dosage-form groups in the Orange Book
4generic makers listed
  1. Ethinyl Estradiol; Norelgestromin appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 12.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Film, Extended Release, Transdermal

Four or more generic makers listed

Every brand product here is listed as discontinued. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 16 April 2014.

200020052010201520202025203004brand 2001Mylan Technologies Inc, first approval 16 April 2014Amneal Pharmaceuticals Llc, first approval 25 February 2021Teva Pharmaceuticals Usa Inc, first approval 25 August 2021Zydus Pharmaceuticals Usa Inc, first approval 14 September 2023data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Mylan Technologies Inc16 April 20141
Amneal Pharmaceuticals Llc25 February 20211
Teva Pharmaceuticals Usa Inc25 August 20211
Zydus Pharmaceuticals Usa Inc14 September 20231

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

System, Transdermal

Brand listed, no generic listed as marketed

Brand listed as marketed: Gwyn Lo. No generic is listed as marketed.

20202025203001brand 2026data dateExclusivity NP to 28 July 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 28 July 2029Exclusivity NP Gwyn Lo

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.